IAM insider filings
Iambic Therapeutics, Inc. — 29 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-19. Screen IAM transaction legs live →
Insider transaction summary — last 90 days
2026-07-26 to 2026-10-24, from the filings listed below: 29 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 1 insider — 718,750 shares, $11,500,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 48.
- Largest priced transaction: purchase of 718,750 shares @ $16.00 ($11,500,000) by Rachlin Evan Lockwood, filed 2026-10-19.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
+3 more insiders in the window, not shown — every filing appears in the table below.
Recent insider filings — Iambic Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-19 | 4 | Catalio Capital Management, LP — 10% owner Catalio Nexus Fund III, LP — 10% owner Catalio Access Fund VIII, LLC — 10% owner Catalio BH SPV, LLC — 10% owner Petrocheilos George C — 10% owner | Conversion (C): 1,995,749 · Conversion (C): 1,458,290 · Conversion (C): 742,546 · Conversion (C): 1,141,878 (derivative) @ $0 · Conversion (C): 731,187 (derivative) @ $0 · Conversion (C): 122,684 (derivative) @ $0 · +2 more | EDGAR |
| 2026-10-19 | 4 | Vogelstein R Jacob — Director | Conversion (C): 1,995,749 · Conversion (C): 1,458,290 · Conversion (C): 742,546 · Conversion (C): 1,141,878 (derivative) @ $0 · Conversion (C): 731,187 (derivative) @ $0 · Conversion (C): 122,684 (derivative) @ $0 · +2 more | EDGAR |
| 2026-10-19 | 4 | Secora Michael — CFO & Chief Corp Dev Ofcr | Conversion (C): 61,342 · Conversion (C): 61,342 (derivative) @ $0 | EDGAR |
| 2026-10-19 | 4 | RASTETTER WILLIAM H — Director | Conversion (C): 192,579 · Conversion (C): 8,341 · Conversion (C): 76,801 (derivative) @ $0 · Conversion (C): 64,001 (derivative) @ $0 · Conversion (C): 36,805 (derivative) @ $0 · Conversion (C): 14,972 (derivative) @ $0 · +1 more | EDGAR |
| 2026-10-19 | 4 | Rachlin Evan Lockwood — Director | Conversion (C): 1,458,736 · Conversion (C): 410,762 · Purchase (P): 718,750 @ $16 · Conversion (C): 57,754 · Conversion (C): 1,152,025 (derivative) @ $0 · Conversion (C): 57,754 (derivative) @ $0 · +2 more | EDGAR |
| 2026-10-16 | 4 | EMSTER KURT VON — Director | Grant/award (A): 20,300 (derivative) @ $0 | EDGAR |
| 2026-10-16 | 4 | Vogelstein R Jacob — Director, 10% owner | Grant/award (A): 20,300 (derivative) @ $0 | EDGAR |
| 2026-10-16 | 4 | TAGLIAFERRI MARY — Director | Grant/award (A): 20,300 (derivative) @ $0 | EDGAR |
| 2026-10-16 | 4 | Sharp Shalini — Director | Grant/award (A): 20,300 (derivative) @ $0 | EDGAR |
| 2026-10-16 | 4 | RASTETTER WILLIAM H — Director | Grant/award (A): 40,600 (derivative) @ $0 | EDGAR |
| 2026-10-16 | 4 | Rachlin Evan Lockwood — Director | Grant/award (A): 20,300 (derivative) @ $0 | EDGAR |
| 2026-10-16 | 4 | Secora Michael — CFO & Chief Corp Dev Ofcr | Grant/award (A): 28,400 @ $0 · Grant/award (A): 170,300 (derivative) @ $0 | EDGAR |
| 2026-10-16 | 4 | Olson Peter A — Chief Scientific Officer | Grant/award (A): 19,500 @ $0 · Grant/award (A): 116,900 (derivative) @ $0 | EDGAR |
| 2026-10-16 | 4 | Josephson Neil — Chief Medical Officer | Grant/award (A): 31,000 @ $0 · Grant/award (A): 185,900 (derivative) @ $0 | EDGAR |
| 2026-10-16 | 4 | Manby Frederick R — Chief Technology Officer, Director | Grant/award (A): 132,200 @ $0 · Grant/award (A): 793,200 (derivative) @ $0 | EDGAR |
| 2026-10-16 | 4 | Miller Thomas F. — Chief Executive Officer, Director | Grant/award (A): 132,200 @ $0 · Grant/award (A): 793,200 (derivative) @ $0 | EDGAR |
| 2026-10-14 | 3 | Catalio Capital Management, LP — 10% owner Catalio Nexus Fund III, LP — 10% owner Catalio Access Fund VIII, LLC — 10% owner Catalio BH SPV, LLC — 10% owner Petrocheilos George C — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-14 | 3 | EMSTER KURT VON — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-14 | 3 | Vogelstein R Jacob — Director, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-14 | 3 | TAGLIAFERRI MARY — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-14 | 3 | Sharp Shalini — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-14 | 3 | RASTETTER WILLIAM H — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-14 | 3 | Rachlin Evan Lockwood — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-14 | 3 | Hirawat Samit — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-14 | 3 | Secora Michael — CFO & Chief Corp Dev Ofcr | Holdings only — no transactions reported | EDGAR |
| 2026-10-14 | 3 | Olson Peter A — Chief Scientific Officer | Holdings only — no transactions reported | EDGAR |
| 2026-10-14 | 3 | Josephson Neil — Chief Medical Officer | Holdings only — no transactions reported | EDGAR |
| 2026-10-14 | 3 | Manby Frederick R — Chief Technology Officer, Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-14 | 3 | Miller Thomas F. — Chief Executive Officer, Director | Holdings only — no transactions reported | EDGAR |
Recent 8-K events — Iambic Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-16 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — Iambic Therapeutics, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-299057 (S-1) — latest: Final prospectus (424B4), filed 2026-10-15
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IAM returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs